A No voting block & an alternative loan facility, page-126

(Japanese) Love is in the Air!

After almost two years without mentioning Cynata in any of their tweets, first FujiFilm Cellular Dynamics tweeted a reference to CYP-001 (Cynata only in brackets) last week and now the same Tweet was shared by FujiFilm Healthcare:



4 days until the last Cohort B Patient reaches 100 days.

That article was published on 10th July 2018 by the way - more than 6 weeks ago...

In case you don't remember the content of the article that 2 FujiFilm Twitter accounts are referring to:

Japan likely first market
“Japan will be one of the important markets for us due to the availability of the fast track there. One can bring a product to the market at the end of phase II, and assuming Fujifilm exercises its option, then all of the costs associated with further work will be met by Fujifilm,” Macdonald said.
Japan’s Fujifilm Corp. invested $3 million in Cynata in September 2016, and the agreement gives Fujifilm the option to acquire development, manufacturing and licensing rights to CYP-001 in GvHD. In exchange, the Australian company gains access to allogeneic iPS cells supplied by Cellular Dynamics International (CDI), a Fujifilm subsidiary. (See BioWorld, Sept. 21, 2016.)
The Fujifilm deal opens up the second-largest pharma market in the world to Cynata as well as the fast track pathway for the product.
Although GvHD is an orphan indication with a small patient population, it represents a large unmet medical need and an attractive commercial entry point for Cynata. Fujifilm expects $300 million per year from the product for GvHD alone, Macdonald said, and Cynata would get about $30 million a year in royalties, “so there’s a lot of blue sky ahead for us just for GvHD alone.”